Randomized trial · people
Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c
Checked against the paper Randomized trialPublished by PepVault
The takeaway
For people with type 2 diabetes still above target on lower dulaglutide doses, this trial found that switching to tirzepatide lowered HbA1c and weight more than raising the dulaglutide dose.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 282
- Published
- 2025
- Journal
- Ann Intern Med
What they tested
For adults with type 2 diabetes not well controlled on lower doses of dulaglutide, the team tested whether switching to tirzepatide or raising the dulaglutide dose worked better.
How the study was done
A randomized, open-label phase 4 trial in 282 adults with type 2 diabetes at 38 sites in 5 countries, with the main results measured at week 40. All had an HbA1c (hemoglobin A1c) of 7.0% to 9.5% while on a steady dulaglutide dose of 0.75 or 1.5 mg for at least 6 months. They were assigned either to move up to dulaglutide 4.5 mg or the highest dose they could tolerate, or to switch to tirzepatide.

Model. Individual results vary.
What they found
At week 40, HbA1c dropped by 1.44% in the tirzepatide arm (15 mg or the highest tolerated dose) and by 0.67% in the dulaglutide arm (4.5 mg or the highest tolerated dose), an estimated difference of -0.77%. Weight changed by -10.5 kg with tirzepatide and -3.6 kg with dulaglutide, an estimated difference of -6.9 kg. Serious side effects happened in 10 (7.2%) people on tirzepatide and 10 (7.0%) on dulaglutide. Nausea and diarrhea were the most common side effects.
What it doesn’t show
The trial was open-label, meaning participants and staff knew which treatment each person got. It was funded by Eli Lilly and Company.
The paper
Billings et al. Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide : A Randomized Clinical Trial. Ann Intern Med. 2025.
The compounds
More studies on Dulaglutide
- Mazdutide beat dulaglutide on HbA1c and weight at 28 weeksRandomized trial · people · 2026
- Dulaglutide cut HbA1c 1.3 vs 2.4 to 2.8 with tirzepatide at 52 weeksRandomized trial · people · 2022
- Dulaglutide lowered major cardiovascular events (HR 0.88) in REWINDRandomized trial · people · 2019
- Dulaglutide cut HbA1c and weight less than semaglutide in SUSTAIN 7Randomized trial · people · 2018
- 5-Amino-1MQ slowed bladder tumor growth in miceAnimal study · mice · 2024
- MOTS-c prevented muscle atrophy, raised muscle glucose uptake in miceAnimal study · mice · 2024
- Every study on Dulaglutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.